Intraperitoneal 5-fluoro-2?-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study
Cancer Chemotherapy and Pharmacology1995Vol. 37(1-2), pp. 32–38
Citations Over Time
Valerie K. Israel, Chun Jiang, Franco M. Muggia, Anil Tulpule, Susan Jeffers, Lawrence Leichman, C. Paul Morrow, Lynda D. Roman, Cynthia G. Leichman, Kenneth K. Chan
Related Papers
- → Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases(1998)21 cited
- → Effect of Deoxyuridine Coadministration on Toxicity and Antitumor Activity of Fluorouracil and Floxuridine(1975)10 cited
- → Potentiation of the Antitumor Action of 5-Fluorouracil with 5-Ethyl-2′-Deoxyuridine in Human Colorectal Tumor Xenografts(1984)2 cited
- → Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: A phase II study(1989)
- → Combination floxuridine + fluorouracil shows promise in patients with colorectal cancer and liver metastases(1991)